A pregnant woman on her 3rd trimester received a dose of Arexvy.; A pregnant woman on her 3rd trimester received a dose of Arexvy; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of vaccine exposure during pregnancy in a adult female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: A pregnant woman on her 3rd trimester received a dose of Arexvy.) and drug use in unapproved population (Verbatim: A pregnant woman on her 3rd trimester received a dose of Arexvy). The outcome of the vaccine exposure during pregnancy and drug use in unapproved population were unknown. Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 10-JAN-2025 The pharmacist reported that they administered a dose of Arexvy to a pregnant woman which led to drug use in unapproved population. The patient was on her 3rd trimester of pregnancy and she was in her mid 30’s of age. The pharmacist asked safety information about this.